News

In exchange for these rights, which include a license to intellectual property (IP) that Targeted Genetics may find necessary to develop and commercialize an Huntington’s disease (HD) product,

Additionally, Thalidomide Pharmion was granted marketing approval in combination with dexamethasone for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of

Yiaco Medical serves 18 countries and represents 80 healthcare companies in the Middle East and North Africa with a population of more than 400 million. Hamed Hamadah, chairman

These patents cover prostate and breast imaging applications and are the basis of ProUroCare’s ProUroScan prostate imaging system that is in development. Acquiring these patents, which until now

The proceeds from this transaction will be used to fund the confirmatory Phase III Star trial of the investigational drug Zenvia (dextromethorphan/quinidine) and submit a complete response to

The primary objective of the Phase I study is to evaluate the systemic absorption of menadione topical lotion as an emergent and pre-emergent (prophylactic) treatment for Epidermal Growth

The Advanced Transdermal Delivery (ATD) Gel System is responsible for the enhanced bioavailability of Anturol (oxybutynin), Elestrin (estradiol), LibiGel (testosterone), the Nestorone and estradiol ATD contraceptive and JZP-7

The initial results are expected before the end of May, 2008. These animal studies will be conducted by Krishna Menon, a world-renowned authority in preclinical and toxicological studies

The data showed that sustained disability progression was significantly less likely (by approximately 50%) in those patients receiving MN-166 at either 30 or 60mg per day for 24